| 51st week of 2011 patent applcation highlights part 51 |
| Patent application number | Title | Published |
|---|
| 20110312990 | Diamine Derivatives - A compound represented by the general formula (1): | 2011-12-22 |
| 20110312991 | ACTIVATED BLOOD COAGULATION FACTOR INHIBITOR - An object of the present invention is to provide a novel salt form of a compound that exhibits an inhibitory effect on activated blood coagulation factor X, and is useful as a preventive and/or therapeutic drug for thrombotic diseases, and crystals thereof. The present invention provides N | 2011-12-22 |
| 20110312992 | Inhibitors of C-Kit and Uses Thereof - Compounds and methods useful as inhibitors of c-Kit are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of c-Kit and processes for synthesizing these compounds are also described herein. | 2011-12-22 |
| 20110312993 | AMIDO-TROPANE DERIVATIVES - The present invention relates to a compound of formula I | 2011-12-22 |
| 20110312994 | BIPHENYL DERIVATIVES - This invention provides biphenyl derivatives of formula I: | 2011-12-22 |
| 20110312995 | BRIDGED AND FUSED HETEROCYCLIC ANTIDIABETIC COMPOUNDS - This invention provides for certain bridged and fused heterocyclic compounds of the formula (I) or a pharmaceutically acceptable salt, ester solvate or prodrug thereof wherein: L is: (II) and the other variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders. | 2011-12-22 |
| 20110312996 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 2011-12-22 |
| 20110312997 | Inhibition of WDR5 Interaction with Its Binding Partners - Peptidomimetics that inhibit the interaction between MLL1 and WDR5 are disclosed. Methods of inhibiting MLL1 activity and methods of treating cancers also are disclosed. | 2011-12-22 |
| 20110312998 | Methods of Making and Using Stable Pharmaceutical Compositions Comprising Ketotifen and Naphazoline - Stable compositions comprising ketotifen or a ketotifen salt and methods of preparing such compositions are provided. The pH of the compositions remains at less than about 5 during storage. The methods comprise preparing pharmaceutical compositions comprising ketotifen or a ketotifen salt, and adjusting their pH to less than 5, thus slowing the changes of the active ingredients. | 2011-12-22 |
| 20110312999 | Ketoheteroarylpiperidine and -Piperazine Derivatives as Fungicides - Ketoheteroarylpiperidine and -piperazine derivatives of the formula (I), | 2011-12-22 |
| 20110313000 | CCR9 INHIBITORS AND METHODS OF USE THEREOF - The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods. | 2011-12-22 |
| 20110313001 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE - According to the invention there is provided a compound of formula (I): (I) or a pharmaceutically acceptable salt or hydrate thereof; wherein the variables are as defined herein. The compounds selectively attenuate the production of Aβ42 and hence are useful in treatment of Alzheimer's disease and related conditions. | 2011-12-22 |
| 20110313002 | TRICYCLIC COMPOUNDS - The present invention provides novel compounds of formula I, | 2011-12-22 |
| 20110313003 | GPR120 RECEPTOR AGONISTS AND USES THEREOF - GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control. | 2011-12-22 |
| 20110313004 | DEUTERATED PYRIDINONES - This invention relates to novel substituted pyridinones, their deuterium-modified derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a TNF (tumor necrosis factor) alpha production inhibitor/TGF (transforming growth factor) beta inhibitor. | 2011-12-22 |
| 20110313005 | TOPICALLY APPLICABLE PHARMACEUTICAL PREPARATION - A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form. | 2011-12-22 |
| 20110313006 | PHARMACEUTICAL COMPOSITION OF LEVAMLODIPINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND .beta. RECEPTOR BLOCKING AGENT, AND USE THEREOF - A pharmaceutical composition of levamlodipine or a pharmaceutically acceptable salt thereof and a β receptor blocking agent, and a use thereof are provided. An active ingredient of the pharmaceutical composition contains levamlodipine or a pharmaceutically acceptable salt thereof, and a β receptor blocking agent, in which the β receptor blocking agent is one selected from nebivolol, bisoprolol, betaxolol, celiprolol, and nadolol. A use of the pharmaceutical composition in preparation of a medicine for treating hypertension is further provided. The pharmaceutical composition of the prevent invention has the advantages that the therapeutic effect is obvious, and the administration is convenient. | 2011-12-22 |
| 20110313007 | USE OF METFORMIN IN COMBINATION WITH A GLUCOKINASE ACTIVATOR AND COMPOSITIONS COMPRISING METFORMIN AND A GLUCOKINASE ACTIVATOR - The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator. | 2011-12-22 |
| 20110313008 | PENTAFLUOROSULPHOLANE-CONTAINING ANTIDIABETIC COMPOUNDS - This invention provides for certain pentafluorosulpholane-containing compounds of the formula or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof, wherein the variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders. | 2011-12-22 |
| 20110313009 | NSAID DOSE UNIT FORMULATIONS WITH H2-RECEPTOR ANTAGONISTS AND METHODS OF USE - The present invention generally relates to unit dosage forms of naproxen and H | 2011-12-22 |
| 20110313010 | COMBINATION OF LOCAL TEMOZOLOMIDE WITH LOCAL BCNU - The additive effect of combined intracranial carmustine (“BCNU”) with intracranial temozolomide (“TMZ”), and particularly in combination with radiation (“XRT”), in the treatment of two rat intracranial glioma models, the 9L gliosarcoma and the F98 glioma, demonstrates that local delivery of both drugs, especially in combination with radiation, is far more effective than delivery of either drug alone or one systemically and one locally, either with or without radiation. The triple therapy showed a significant improvement in survival when compared to controls (p=0.0004), local BCNU (p=0.0043), oral TMZ (p=0.0026), local TMZ (p=0.0105), and the combinations of either BCNU and XRT (p=0.0378) or oral TMZ and local BCNU (p=0.0154). | 2011-12-22 |
| 20110313011 | Amino Acid Compounds - A method for increasing the bioabsorption of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, and Valine. | 2011-12-22 |
| 20110313012 | Amino Acid Compounds - A method for increasing the vasodilative characteristics of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, and Valine. | 2011-12-22 |
| 20110313013 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE - Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit uptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided. | 2011-12-22 |
| 20110313014 | PRODUCTS COMPRISING N-PHENYLPROPENOYL AMINO ACID AMIDES AND USES THEREOF - The present invention relates to use of a composition comprising N-phenylpropenoyl amino acid amides for the preparation of a product to treat or prevent neurodegenerative disorders, cognitive decline, mild cognitive impairment, dementia, mood disorders, depression, sleep disorders, diseases involving protein aggregation in a human or animal, Alzheimer's disease, macular degeneration or diabetes. The invention further relates to products comprising N-phenylpropenoyl amino acid amides, including food and beverage products, food supplements, and pet food products, and methods for affecting cognitive performance of humans and animals. | 2011-12-22 |
| 20110313015 | Fludioxonil Derivatives - The present invention relates to the novel fludioxonil derivatives, to processes for their preparation, to their use for controlling unwanted microorganisms, in particular phytopathogenic fungi, or to their use for controlling unwanted broad-leaved weeds and weed grasses of useful plants in each case in crop protection, in the domestic and hygiene field and in the protection of materials, and also to crop protection compositions comprising these fludioxonil derivatives. | 2011-12-22 |
| 20110313016 | Treatment of Intestinal Conditions - Methods and compositions for the treatment of intestinal disorders, such as IBD and Crohn's disease, are disclosed. Preferred compositions include siNA. Also disclosed is a method of specifically targeting siNA to treat intestinal disorders by intrarectal administration of siNA compounds. | 2011-12-22 |
| 20110313017 | SNALP FORMULATIONS CONTAINING POLYOXAZOLINE-DIALKYLOXYPROPYL CONJUGATES - The present invention provides polyoxaline-dialkyloxypropyl conjugates (POZ-DAA), SNALP compositions comprising POZ-DAA conjugates and methods of using such SNALP compositions to introduce a therapeutic agent, such as a nucleic acid, into a cell (e.g., for the treatment of a disease or disorder). | 2011-12-22 |
| 20110313018 | CANCER RELATED GENE, LGN/GPSM2 - The present invention provides methods for detecting and diagnosing cancer, which method involves the determination of the expression level of the LGN/GPSM2 gene. Furthermore, the present invention provides methods of screening for therapeutic agents useful in the treatment or prevention of cancer and methods for treating breast cancer. Moreover, the present invention provides siRNAs targeting the LGN/GPSM2 gene, which are useful in the treatment or prevention of cancer. | 2011-12-22 |
| 20110313019 | OLIGOMERIC COMPOUNDS AND METHODS - The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds. | 2011-12-22 |
| 20110313020 | UsiRNA Complexes - This disclosure provides double-stranded RNA complexes having one or more hydroxymethyl substituted nucleomonomer(s) in the passenger strand (or sense strand) of an RNA complex. RNA complexes of the disclosure may be useful for therapeutic applications, diagnostic applications or research applications. RNA complexes include short interfering RNA complexes (siRNA) capable of modulating gene expression comprising an antisense strand and a continuous or a discontinuous passenger strand (“sense strand”). Further, one or more hydroxymethyl substituted nucleomonomer(s) of this disclosure may be positioned at the 3′-end, at the 5′-end, at both the 3′-end and 5′end. | 2011-12-22 |
| 20110313021 | Method to rapidly identify critical p53 target genes that can be utilized for therapeutic intervention - The majority of human cancers inactivate the p53 tumor suppressor network, and consequently, p53 is one of the most studied proteins in cancer biology. Peering into the intricacies of the p53 network should provide insight into the etiology of cancer, which may lead to the identification of molecular targets for therapeutic intervention. p53 carries out its tumor suppressor functions by inducing potent biological outputs, such as programmed cell death, in cells destined for becoming cancerous. p53 is a transcription factor that can regulate expression of numerous genes. The present invention discloses a novel method of rapidly determining the critical p53 target genes that can be utilized for therapeutic intervention. Additionally, this invention discloses suppression of MCAK as a treatment of human cancers and other diseases where p53 levels are elevated. | 2011-12-22 |
| 20110313022 | Compositions and Methods for Diminishing Viral Infection and Inflammation Associated with Viral Infection - The invention relates to compositions and methods for preventing and diminishing virus infection. The invention further relates to compositions and methods for diminishing inflammation associated with viral infection. The invention also relates to compositions and methods for interfering with TLR activation, and thereby diminishing inflammation associated with viral infection. | 2011-12-22 |
| 20110313023 | RNAi MODULATION OF RSV AND THERAPEUTIC USES THEREOF - The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses. | 2011-12-22 |
| 20110313024 | RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression and/or activity. Specifically, the invention relates to double stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. | 2011-12-22 |
| 20110313025 | METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES - The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays. | 2011-12-22 |
| 20110313026 | DNA AND PROTEINS OR PEPTIDES SPECIFIC OF BACTERIA OF THE NEISSERIA MENINGITIDIS SPECIES, METHODS FOR OBTAINING THEM AND BIOLOGICAL APPLICATIONS THEREOF - The DNA of the invention are characterised in that they concern the whole or part of genes, with their reading frame, to be found in | 2011-12-22 |
| 20110313027 | METHODS AND SUBSTANCES FOR STIMULATING MUSCLE REGENERATION - The invention is concerned with the field of muscle growth and regeneration. More particularly, the invention provides novel methods, substances and uses for facilitating the growth or regeneration of skeletal muscles. The methods, uses and substances of the invention are useful in the treatment or prevention of degenerative-regenerative muscular disorders or in the treatment of muscle injuries. The substances provided by the invention are capable of upregulating the calcineurin-NFAT-IL-4, advantageously by inhibiting the activity of the Ras or SERCA1b gene product. Introduction of the substances provided by the invention into only a small percentage of the fibers present in a regenerating muscle facilitates the regeneration of the whole muscle concerned. | 2011-12-22 |
| 20110313028 | SUPPRESSOR OF AP-1 - Methods, compositions, and therapeutic products for use in the field of oncology and specifically, for the treatment of cancer and other diseases in which SARI is ameliorative or therapeutic and/or small molecule screening for anti-cancer drugs are provided. Cancer specific gene expression using the CCN1 promoter, which is negatively regulated by SARI, for targeting therapeutic molecules in tumors is also provided. | 2011-12-22 |
| 20110313029 | DIAGNOSTIC AND THERAPEUTIC USES OF GNPTAB, GNPTG, AND NAGPA IN STUTTERING - The allelic variants or mutations in three genes: GNPTAB, GNPTG and NAGPA, that correlate with stuttering in humans, as well as the encoded mutated polypeptides and related vectors, host cells, antibodies, antibody-producing cell lines and methods of diagnosing, prognosticating and treating stuttering are provided. | 2011-12-22 |
| 20110313030 | PKR ACTIVATION VIA HYBRIDIZATION CHAIN REACTION - The present application relates to the use of hybridization chain reaction (HCR) to form double stranded RNA polymers in the presence of a target, such as a nucleic acid associated with a disease or disorder. The RNA polymers are preferably able to activate the RNA-dependent kinase PKR. Activation of PKR via RNA-HCR can be used to treat a wide variety of diseases and disorders by specifically targeting diseased cells. | 2011-12-22 |
| 20110313031 | OLIOODEOXYNUCLEOTIDE AND ITS USE TO INDUCE AN IMMUNE RESPONSE - A substantially pure or isolated oligodeoxynucleotide of at least 10 nucleotides is disclosed, wherein the oligodeoxynucleotide comprised a sequence represented by either formula: | 2011-12-22 |
| 20110313032 | COMPETITIVE INHIBITORS OF TYPE II DEHYDROQUINASE ENZYME - The present invention is directed to a compound of formula (I), its diastereoisomers, its enantiomers or its pharmaceutically acceptable salts or solvates, formula (I), to procedures of obtaining the same, to intermediates thereof, and use as competitive inhibitors of the third enzyme of the shikimic acid pathway, the type II dehydroquinase. | 2011-12-22 |
| 20110313033 | OPHTHALMIC USES OF S1P RECEPTOR MODULATORS - The present invention pertains to the use of a S1P receptor agonist in the manufacture of a medicament in the treatment of an ocular disorder. | 2011-12-22 |
| 20110313034 | NEUROACTIVE PLANT EXTRACT FROM HYPERICUM POLYANTHEMUM - The present invention belongs to the field of plant extracts with activity on the central nervous system. Specifically, the plant extract of the present invention is an extract obtained from | 2011-12-22 |
| 20110313035 | POLYMORPHS OF DARUNAVIR - The present invention provides novel solvated forms of darunavir and processes for there preparation. The present invention also provides novel process for preparation of darunavir amorphous form and pharmaceutical composition comprising it. Thus, for example, darunavir 2-methyl-2-butanol solvate was dissolved in methylene dichloride, distilled under vacuum at 45° C. to obtain a residue, cyclohexane was added to the residue and stirred for 30 hours at 20 to 25° C., and the separated solid was filtered, washed with cyclohexane and dried under vacuum at 50° C. for 12 hours to yield darunavir amorphous form. | 2011-12-22 |
| 20110313036 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG - A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided. | 2011-12-22 |
| 20110313037 | [2.2.2] Bicyclic Derivatives and Methods of Use - Administration of a salt of bi-cyclo[2.2.2]octane-2-carbonic acid reduces dysphoria in dysphoric subjects, ameliorates ethanol craving in alcoholics, reduces the erythrocyte sedimentation rate and the level of liver function markers (AST, ALT, and bilirubin) in human subjects, and reduces the number or strength of seizures in epileptics. | 2011-12-22 |
| 20110313038 | CATIONIC OIL-IN-WATER EMULSIONS CONTAINING PROSTAGLANDINS AND USES THEREOF - A colloidal cationic oil-in-water emulsion includes: —a prostaglandin, —an oil having a iodine value ≦2, —one or more surfactants including at least one quaternary ammonium compound, —water, wherein the prostaglandin/total sum of surfactants mass ratio is included between 0.5 and 5. The use of the cationic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described. | 2011-12-22 |
| 20110313039 | METHOD FOR INCREASING ENDOGENOUS PLASMALOGEN LEVELS IN MAMMALS - The present invention relates generally to compounds such as alkylglycerol and alkoxyglycerol for use in increasing the endogenous level of plasmalogens in a mammal. In particular, these compounds are used for increasing the endogenous plasmalogen level to a level greater than the level in healthy mammals. According to the present invention such compounds are also for use in the prevention or treatment of diseases caused or affected by a decreased endogenous level of plasmalogens. A method for the manufacture of a dietary precursor for the use of the present invention is also part of the present disclosure. | 2011-12-22 |
| 20110313040 | ORGANIC NUTRIENT SALTS, METHODS OF PREPARATION AND USES - The invention relates to organic nutrient salts, to compositions containing the same, to their preparation as well as their use. Preferred compositions include nutraceutical compositions and dietary supplements for use in neuroprotection and for improving or protecting cognitive and memory function. | 2011-12-22 |
| 20110313041 | FOOD SUPPLEMENTS ON THE BASIS OF PANTOTHENIC ACID - The present invention relates to a dietary supplement for the treatment of weakness in metabolic activity containing Pantothenic acid (CoA), its precursors and/or its salts, a process for its production as well as its use. Application areas of the invention are food industry and medicine. | 2011-12-22 |
| 20110313042 | Amino Acid Compositions - An amino acid composition is disclosed. The composition includes: at least one constituent selected from the group consisting of a nitrate, a nitrite, and both; and at least one constituent amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, Valine, Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, and Phenylalanine Also disclosed are a method for increasing the bioabsorption of Amino Acids in a human or animal and a method for increasing vasodilative characteristics of Amino Acids in a human or animal. | 2011-12-22 |
| 20110313043 | Amino Acid Compositions - Methods for increasing athletic performance, distribution of various Amino Acids to muscles, and solubility of various Amino Acids in a human or animal by administering an amino acid composition that includes: at least one constituent selected from the group consisting of a nitrate, a nitrite, and both; and at least one constituent amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, Valine, Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, and Phenylalanine | 2011-12-22 |
| 20110313044 | Polymorphs of Suberoylanilide Hydroxamic Acid - The present invention is directed to a novel form of suberoylanilide hydroxamic acid and the processes for its preparation. | 2011-12-22 |
| 20110313045 | HISTONE DEACETYLASES, AND USES RELATED THERETO - The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell proliferation and differentiation in vitro and in vivo. | 2011-12-22 |
| 20110313046 | COMBINATION THERAPY WITH LISDEXAMPHETAMINE AND EXTENDED RELEASE GUANFACINE - The present invention relates to treating children and adults with suboptimal responses to Attention Deficit Hyperactivity Disorder (ADHD) monotherapy. More specifically, the present invention relates to a method for treating ADHD in a patient which comprises administering to the patient an extended release guanfacine composition adjunctively with a lisdexamphetamine composition. | 2011-12-22 |
| 20110313047 | DELIVERY SYSTEM FOR HIGH CONCENTRATION OF CERAMIDE - The present invention is directed to a delivery system capable of solubilizing high concentrations of ceramide, the system containing: (a) at least one C1-C4 monoalcohol; (b) at least one C6-C22 fatty acid and/or alcohol; and (c) from about 5 to about 14% by weight, based on the weight of the composition, of at least one ceramide. | 2011-12-22 |
| 20110313048 | ANTIMICROBIAL SILICONE-BASED WOUND DRESSINGS - Antimicrobial silicone-based dressings, such as wound dressings, are disclosed. An example dressing comprises a transparent and self-adhesive gel sheet cured from a liquid containing silicone, the sheet having dispersed therein (i) particulates of a chlorhexidine compound that is not soluble in the liquid; and (ii) at least one other antimicrobial. Methods of making the silicone-based dressings and methods of use are also disclosed. | 2011-12-22 |
| 20110313049 | ANTIBACTERIAL COMPOSITIONS COMPRISING QUATERNARY AMMONIUM GERMICIDES AND ALKAMINE OXIDES HAVING REDUCED IRRITATION POTENTIAL - Antibacterial compositions having antibacterial effectiveness and reduced eye irritation potential are disclosed. The antibacterial compositions contain a quaternary ammonium compound, an alkamine oxide, a nonionic compound, optional adjuvant materials known in the art, and water. The eye irritation is decreased by decreasing the amount, by weight, of alkamine oxide present in the composition and alternatively, or in combination therewith, increasing the ratio of nonionic material to alkamine oxide present in the composition. | 2011-12-22 |
| 20110313050 | SOLID COMPOSITION CONTAINING THE INGREDIENT RASAGILINE - The present invention relates to a solid composition containing at least one pharmaceutically compatible auxiliary ingredient and rasagiline or a pharmaceutically compatible salt thereof as an active ingredient. The invention further relates to a method for producing said solid composition and to a medicine comprising said solid composition. | 2011-12-22 |
| 20110313051 | Delivery system for topical medications - The present invention is a delivery system comprising a pad and a liquid composition, comprising an insoluble dermatologically active ingredient with a viscosity that permits substantially uniform absorption of the composition onto the pad, and the pad is in then packaged in a sealed container. | 2011-12-22 |
| 20110313052 | Composition Comprising Biodegradable Carrier for Controlled Delivery - The present invention relates to a controlled release medical composition comprising: a powder composition of a binder; a water based liquid; and a medical active pharmaceutical ingredient. In a first embodiment the powder composition comprises at least calcium carbonate of a first phase and calcium carbonate of a second different phase, the first and second phase are selected from the group: amorphous calcium carbonate; vaterite; aragonite; and calcite; and in a second embodiment the powder composition comprises calcium carbonate, or calcium sulphate, or calcium phosphate, or combinations thereof. | 2011-12-22 |
| 20110313053 | Thickeners Based on Polyurethane - Thickeners, which are based on an aqueous preparation of nonionic water-dispersible or water-soluble polyurethanes, it being possible to produce these polyurethanes by reacting
| 2011-12-22 |
| 20110313054 | BRANCHED COPOLYMERS, COMPOSITION AND USES - The present invention relates to a branched copolymer obtainable by an addition polymerisation process and uses and compositions thereof comprising a hydrophilic component, said polymer comprising:
| 2011-12-22 |
| 20110313055 | HEALTH CHARACTERISTIC CHEWY OR GUMMY CANDY CONFECTION - The present invention provides for flavored chewy or gummy candy confections made by making a flavored chewy or gummy candy confection from scratch or adjusting a current flavored chewy or gummy candy confection brand product with our invention. This invention can have a healthier group of edible oils component, unique antioxidant taste profile component, fiber component, water component, emulsifier component, and potentially a 0% or greater supplement component that can add additional dietary benefits. Specific ratios of ingredients can lower sugar content up to 75% while creating a product with a taste, texture, and mouth feel similar to regular flavored chewy or gummy candy. The reduction of sugar possible within this invention can reduce the negative health ramifications of high sugar content that current flavored chewy or gummy candy confections suffer from and the addition of the healthier ingredients adds some improved health characteristics to the products that usually are devoid of nutrition. Additionally, the method for preparing a flavored chewy or gummy candy confection with these improved health characteristics, taste profile, and dietary benefits are covered. | 2011-12-22 |
| 20110313056 | GEL FORMATION OF POLYELECTROLYTE AQUEOUS SOLUTIONS BY THERMALLY INDUCED CHANGES IN IONIZATION STATE - There is disclosed aqueous solutions of polyelectrolytes that can be neutralized by increasing temperature, under suitable polyelectrolyte charge state conditions, in order to obtain a homogeneous gel. This can be achieved by adding an appropriate weak electrolyte to the polyelectrolyte so that an increase of temperature will lead to a spatially homogeneous neutralization of the polyelectrolyte via proton transfer between the polyelectrolyte and the weak electrolyte. The ability of such a system to be thermally sensitive and to gel upon heating relies on the temperature dependence of the ionization equilibrium for the two components. This thermally induced neutralization reduces electrostatic repulsion between polyelectrolyte molecules allowing the manifestation of attractive polyelectrolyte-polyelectrolyte hydrophobic interactions and hydrogen bonding that result in gel formation. These new kinds of thermo sensitive gels can be used for biomedical applications. | 2011-12-22 |
| 20110313057 | DIFUNCTIONALIZED AROMATIC COMPOUNDS AND POLYMERS THEREFROM - The present invention relates to compounds of formula I, which are difunctionalized aromatic compounds, and polymers formed from the same. | 2011-12-22 |
| 20110313058 | METHOD AND APPARATUS FOR LIMITING GROWTH OF EYE LENGTH - Certain embodiments of the present invention are directed to therapeutic intervention in patients with eye-length-related disorders to prevent, ameliorate, or reverse the effects of the eye-length-related disorders. Embodiments of the present invention include methods for early recognition of patients with eye-length-related disorders, therapeutic methods for inhibiting further degradation of vision in patients with eye-length-eye-length-related disorders, reversing, when possible, eye-length-related disorders, and preventing eye-length-related disorders. Additional embodiments of the present invention are directed to particular devices used in therapeutic intervention in patients with eye-length-related disorders. | 2011-12-22 |
| 20110313059 | PROCESS FOR PREPARING STABLE SUSPENSIONS OF METAL NANOPARTICLES AND THE STABLE COLLOIDAL SUSPENSIONS OBTAINED THEREBY - A process is described for preparing stable suspensions of metal nanoparticles by means of a microwave-assisted metal nanoparticle synthesis undertaken in an aqueous environment at low temperature and at ambient pressure and atmosphere. | 2011-12-22 |
| 20110313060 | Silicone Dispersions - A non-aqueous silicone emulsion is provided. It comprises a continuous phase of a polar organic liquid containing droplets of an organopolysiloxane dispersed therein. An organic wax, which has a melting point in the range 40 to 100° C. and is sparingly soluble in the polar organic liquid at 25° C., is dispersed in the polar organic liquid continuous phase as a network of interconnected particles which stabilises the organopolysiloxane droplets in emulsion in the polar organic liquid. A process for the production of the emulsion is also disclosed. | 2011-12-22 |
| 20110313061 | PROTECTED FISCHER-TROPSCH CATALYST AND METHOD OF PROVIDING SAME TO A FISCHER-TROPSCH PROCESS - A method of preparing a spray dried catalyst by combining spray dried catalyst particles with wax so the spray dried catalyst particles are coated with wax, yielding wax coated catalyst particles, and shaping the wax coated catalyst to provide shaped wax coated catalyst. A method of activating Fischer-Tropsch catalyst particles containing oxides by contacting the catalyst particles with a reducing gas in an activation vessel to produce an activated catalyst, wherein contacting is performed in the absence of a liquid medium under activation conditions. A system for activating a Fischer-Tropsch catalyst containing an activation reactor configured to introduce an activation gas to a fixed or fluidized bed of the Fischer-Tropsch catalyst in the absence of a liquid medium and at least one separation device configured to separate a gas stream comprising entrained catalyst fines having an average particle size below a desired cutoff size from the activation reactor. | 2011-12-22 |
| 20110313062 | SLURRY BUBBLE COLUMN REACTOR - A slurry bubble column reactor with a gas distribution arrangement comprising an upper sparger, a lower sparger, and an open-ended tube. Gas from the lower sparger enters the tube and lowers the density of slurry in the tube. The difference in slurry density causes the slurry in the tube to rise, causing slurry outside the tube to move down, maintaining circulation and flushing catalyst from the vessel wall. | 2011-12-22 |
| 20110313063 | APPARATUS AND METHOD FOR CONDUCTING A FISCHER-TROPSCH SYNTHESIS REACTION - A system for a Fischer-Tropsch synthesis using a three-phase reactor in which a primary filter removes coarse catalyst particles from the product and in which catalyst fines are removed in a secondary filter. Some or all portion of the product wax from the secondary filter can be recycled back to the reactor, either as a back flush medium for the primary filter or directly to the slurry in the reactor, whereby removal of catalyst fines is rendered independent of the rate of wax production. | 2011-12-22 |
| 20110313064 | RECOVERY OF CO2 IN A PROCESS FOR SYNTHESIS OF METHANOL - A process for producing methanol, where a hydrocarbon feedstock ( | 2011-12-22 |
| 20110313065 | METHOD FOR RECOVERING HYDROCARBON COMPOUNDS AND A HYDROCARBON RECOVERY APPARATUS FROM A GASEOUS BY-PRODUCT - There is provided a method for recovering hydrocarbon compounds from a gaseous by-products generated in the Fisher-Tropsch synthesis reaction, the method comprising a pressurizing step in which the gaseous by-products are pressurized, a cooling step in which the pressurized gaseous by-products are pressurized to liquefy hydrocarbon compounds in the gaseous by-products, and a separating step in which the hydrocarbon compounds liquefied in the cooling step are separated from the remaining gaseous by-products. | 2011-12-22 |
| 20110313066 | STIMULUS RESPONSIVE POLYMERS FOR THE PURIFICATION OF BIOMOLECULES - The present invention provides novel and improved stimulus responsive polymers and methods of using the same for the purification of biomolecules. | 2011-12-22 |
| 20110313067 | ORGANIC, OPEN CELL FOAM MATERIALS, THEIR CARBONIZED DERIVATIVES, AND METHODS FOR PRODUCING SAME - Organic, small pore area materials (“SPMs”) are provided comprising open cell foams in unlimited sizes and shapes. These SPMs exhibit minimal shrinkage and cracking. Processes for preparing SPMs are also provided that do not require supercritical extraction. These processes comprise sol-gel polymerization of a hydroxylated aromatic in the presence of at least one suitable electrophilic linking agent and at least one suitable solvent capable of strengthening the sol-gel. Also disclosed are the carbonized derivatives of the organic SPMs. | 2011-12-22 |
| 20110313068 | EXTRUDED POLYMER FOAMS CONTAINING ESTERS OF A SUGAR AND A BROMINATED FATTY ACID AS A FLAME RETARDANT ADDITIVE - An ester of a sugar and a brominated fatty acid is a useful FR additive for combustible polymers. The brominated FR additives unexpectedly are stable at the extrusion temperatures, and provide excellent flame retardancy to the combustible polymers. | 2011-12-22 |
| 20110313069 | FLAME-RETARDED FOAMABLE STYRENE-BASED RESIN COMPOSITIONS - In a flame-retarded foamable styrene-based resin composition comprising a bromine-containing flame retardant, the flame retardant is a mixture of (a) an organic bromine-containing compound having a 2,3-dibromopropyl group or an organic bromine-containing compound having a bromine content of greater than 60 wt % in which all bromine atoms are attached to a benzene ring, and (b) an organic bromine compound having a 2,3-dibromo-2-alkylpropyl group. The composition comprises this mixture in amount from 0.5 to 10 parts by weight per 100 parts by weight of the styrene-based resin. The composition exhibits high flame retardant and heat stabilizing effects yet allowing recycling. | 2011-12-22 |
| 20110313070 | PROCESS FOR PRODUCING SILICA-COMPRISING DISPERSIONS COMPRISING POLYETHEROLS OR POLYETHER AMINES - Process for producing silica-comprising dispersions comprising a polyetherol or a polyether amine, which comprises the steps of
| 2011-12-22 |
| 20110313071 | Polyethylene molding powder and porous articles made therefrom - The present invention relates to a new molding powder comprising polyethylene polymer particles. The molecular weight of the polyethylene polymer is within the range of from about 600,000 g/mol to about 2,700,000 g/mol as determined by ASTM 4020. The average particle size of the particles of the polyethylene polymer is within the range of from about 5 microns to about 1000 microns and the polyethylene has a powder bulk density in the range of from about 0.10 to about 0.30 g/cc. Also disclosed is a process for molding a shape from a molding powder comprising the inventive polyethylene polymer particles, as well as porous articles made in accordance with the process. The articles have excellent porosity and good strength for porous and porous filtration applications. | 2011-12-22 |
| 20110313072 | METHOD FOR MANUFACTURING A PLURALITY OF SHAPED FOAM ARTICLES - The present invention is a method to manufacture one or more shaped foam article. Specifically, the present invention is a method of extruding a thermoplastic polymer with a blowing agent to form a foam polymer plank having a density gradient. Preferably, shaped articles are prepared from the surface of the foam plank having the lowest density. The article is shaped by a mold comprising one or a plurality of cavities wherein the periphery of each cavity is defined by a trimming rib, said mold concurrently shapes the foam article and trims the resulting shaped foam article from the surrounding continuous unshaped foam plank. Preferably, the foam has a vertical compressive balance (Rv) equal to or greater than 0.4 and more preferably, the foam has a cell gas pressure less than 1 atmosphere and/or an open cell content of equal to or less than 20 percent. | 2011-12-22 |
| 20110313073 | FOAM-LIKE MATERIALS AND METHODS FOR PRODUCING SAME - Described herein are foam-like materials having substantially the same physical structure of polyurethane foams but with properties that can be tailored for a particular application. Methods of forming these foam-like materials are also described. | 2011-12-22 |
| 20110313074 | NOVEL POLYOLS DERIVED FROM A VEGETABLE OIL USING AN OXIDATION PROCESS - A method for producing a vegetable oil-derived polyol having increased hydroxyl functionality by reacting a vegetable oil with an oxidizing agent in the presence of an organometallic catalyst is provided. The resulting higher functionality polyols derived from vegetable oil produced by the process are also provided. Also provided is a method for decreasing the acid value of a vegetable oil-derived polyol by reacting the vegetable oil-derived polyol with an epoxide component in the presence of a Lewis base catalyst. Urethane products produced using higher functional vegetable oil-derived polyols and/or lower acid vegetable oil-derived polyols are also provided. | 2011-12-22 |
| 20110313075 | ALIPHATIC POLYESTER - The present invention provides a copolymer obtainable by condensation of
| 2011-12-22 |
| 20110313076 | GASKET-FORMING MATERIAL FOR HARD DISK AND GASKET FOR HARD DISK USING THE SAME - Provided are a gasket-forming material for a hard disk device providing a gasket which can improve a reworking property of a cover plate and a base plate in a hard disk device and a gasket prepared by using the above material. | 2011-12-22 |
| 20110313077 | Polymer material, opthalmic lens and contact lens - Provided is a polymer material having superior water wettability and lubricity, and enabling persistence of the same by allowing the surfactant to be retained by the polymer material so as not to be gradually released. The present invention is directed to a polymer material including: | 2011-12-22 |
| 20110313078 | PASTE-LIKE BONE CEMENT - A kit is provided based on two pastes designed to produce bone cement with high initial stability and therefore low post-cure. The kit includes a paste A and a paste B, wherein paste A contains (a1) a polymerizable monomer having a pH in water in the range of 5-9, (a2) a filling agent insoluble in (a1), and (a3) a barbituric acid derivative selected from the group consisting of 1,5-disubstituted barbiturates, 1,3,5-trisubstituted barbiturates, and 1,3,5-tetrasubstituted barbiturates, and paste B contains (b1) a polymerizable monomer having a pH in water in the range of 5-9, (b2) a filling agent insoluble in (b1), (b3) a peroxide soluble in (b1), (b4) a heavy metal compound insoluble in (b1) and selected from the group consisting of heavy metal salts and heavy metal complexes, and wherein at least one of the pastes A and B contains a halide salt. | 2011-12-22 |
| 20110313079 | SOLVENT-ASSISTED CONTINUOUS EMULSIFICATION PROCESSES FOR PRODUCING POLYESTER LATEXES - Various solvent-assisted extrusion processes are disclosed that are suitable for forming high yield, low coarse content, polyester latexes that may be utilized in forming a toner. | 2011-12-22 |
| 20110313080 | BENZOXAZINE RESIN COMPOSITION - The invention provides a benzoxazine resin composition having excellent resistance to heat and moisture and providing excellent handleability when made into prepreg, and prepreg and a fiber-reinforced composite material prepared from the composition. The composition contains (A) a compound having in its molecule a benzoxazine ring represented by the formula (1), (B) an epoxy resin, (C) a curing agent, and (D) a toughness improver: | 2011-12-22 |
| 20110313081 | THERMOSETTABLE COMPOSITION CONTAINING A GLYCIDYLETHER BASED ON TRIMETHYOLPROPANE OCTADECAETHOXILATE - A thermosettable composition including (a) a thermosetting resin and (b) at least one toughening agent; wherein the at least one toughening agent is a glycidyl ether based on trimethylolpropane octadecaethoxilate (TMP-18EO). | 2011-12-22 |
| 20110313082 | EPOXY ADHESIVE COMPOSITIONS WITH HIGH MECHANICAL STRENGTH OVER A WIDE TEMPERATURE RANGE - A heat-curable adhesive composition comprising an epoxy-resin, a combination of core-shell toughening agents, a first curing agent being a linear aliphatic amined and a second curing agent being a cyclic aliphatic amine and a filler wherein the composition can be cured to form structural adhesives of high mechanical strength over a temperature range from −55° C. to up to 135° C. | 2011-12-22 |
| 20110313083 | Two-component mortar compound and its use - A two-component mortar compound including a curable resin component (A) that contains 30% to 45% by weight of at least one radically polymerizable resin, 30% to 45% by weight of fillers, 15% to 25% by weight of cement and 1% to 8% of a thickeners, and including a separately arranged so as to inhibit reaction curing component (B) that contains 1% to 20% by weight of a peroxide, 10% to 35% by weight of water, 40% to 80% by weight of fillers and 0.5% to 5% by weight of thickeners, with the proviso that the sum of the quantities of the constituents of the resin component or of the curing component is always 100% by weight, which is characterized in that the resin component (A) contains 0.01% to 5% by weight of an organic and/or inorganic acid and/or salts and esters thereof, and the invention also describes its use to fasten anchoring means into drilled holes in mineral substrates by means of the chemical reaction of the resin component (A) with the curing component (B). | 2011-12-22 |
| 20110313084 | COATING COMPOSITIONS COMPRISING POLYUREA AND GRAPHITE - The present invention is directed to a coating composition comprising polyurea or, polyurea and polyurethane, and flame retardant. The polyurea is formed from a reaction mixture comprising an isocyanate component; an amine component; and a flame retardant material comprising graphite in the isocyanate and/or amine components. | 2011-12-22 |
| 20110313085 | FLAME-RETARDANT COMPOUND, CONTINUOUS MATERIALS AND PRODUCTS CONSTRUCTED THEREFROM AND METHODS OF MANUFACTURE THEREOF - A zero-halogen flame-retardant compound and continuous materials extruded therefrom comprise poly(ethylene terephthalate) (PET), fire-retardant ingredients melamine cyanurate (MC) and melamine polyphosphate (MPP), and an organo titanate coupling agent. The coupling agent acts as a dispersion agent to the fine powders of PET, MC and MPP and also allows the resin of the fine powders to be compounded at a reduced temperature which prevents degradation of the PET. The compound can be extruded as a thin film, sheet or tubing, and also as a filament or yarn, including monofilaments and multifilaments, which can ultimately be used to construct a protective sleeve. | 2011-12-22 |
| 20110313086 | POLYOXYMETHYLENES FOR DIESEL APPLICATIONS - Thermoplastic molding materials comprising
| 2011-12-22 |
| 20110313087 | INCREASED BULK DENSITY POWDERS AND POLYMERS CONTAINING THEM - The invention provides a treated powder having improved loose bulk density comprising a silanized inorganic powder treated with a long chain fatty acid or salts thereof, wherein the amount of the long chain fatty acid is about 0.25% to about 2 wt %, based on the total weight of the treated powder. | 2011-12-22 |
| 20110313088 | HIGHLY-FILLED SEALANT COMPOSITIONS - A sealant composition comprising a binder and a filler material. The binder comprising a residual pitch product and an elastomeric material and, optionally, asphalt, a microcrystalline wax, and/or oil. The filler material is present in an amount of between about 11 vol. % and about 67 vol. % of the sealant composition. In one embodiment, the filler material is present in an amount of between about 25 wt. % and about 70 wt. % of the sealant composition. | 2011-12-22 |
| 20110313089 | DISPERSION MEDIUM COMPRISING MONOCARBOXYLIC ESTERS FOR PREPARATIONS OF SOLIDS - The invention concerns a composition comprising as component (A): 10% to 97% by weight, based on the total weight of the composition, of one or more monocarboxylic esters of the general formula R | 2011-12-22 |
